Thetis Pharmaceuticals LLC
Drug for liver disease
Thetis Pharmaceuticals LLC is a biopharmaceutical company that is developing novel drugs for treatment of inflammation-related gastrointestinal (GI) diseases with high unmet medical needs.
Our lead candidate, TP-252, is rapidly advancing through pre-clinical evaluations in order to file an Investigational New Drug (IND) application with FDA in early 2018 to begin clinical studies soon afterward.
Our goal is to partner to license or sell TP-252 to a larger pharmaceutical company to bring the product to market, with a target market approval date of 2023.
Gary Mathias, CEO
Aaron Mathias, Director of Business Development